Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 2Sarcoma, Clear Cell 2Myoepithelioma 2Liposarcoma, Myxoid 2Histiocytoma, Angiomatoid Fibrous 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma, Extraskeletal Myxoid 2Sarcoma 1Fibroma 1

Interventions

Doxorubicin 19Radiotherapy 10Ifosfamide 10apatinib 9anlotinib 8Cyclophosphamide 8camrelizumab 7Vincristine 5Dactinomycin 5toripalimab 3Trabectedin 3Radiation Dose Hypofractionation 3Ipilimumab 3Gemcitabine 3Etoposide 3Docetaxel 3selinexor 2ribociclib 2envafolimab 2brostallicin 2Topotecan 2Thalidomide 2Temozolomide 2Sorafenib 2Oncolytic Virotherapy 2Nivolumab 2Neoadjuvant Therapy 2Melphalan 2Magnetic Resonance Spectroscopy 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Sarcoma × seclidemstat × Clear all
NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Salarius Pharmaceuticals, LLC

Phase 1 Unknown
50 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡